Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.
Publications
2 shownREporting recommendations for tumour MARKer prognostic studies (REMARK)
Despite years of research and hundreds of reports on tumour markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often initially...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 6,746
External Links
Identifiers
- ORCID
- 0000-0002-2265-6743
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.